The incidence of COVID-19 in patients with metabolic syndrome and non-alcoholic steatohepatitis: A population-based study.

ABSTRACT:

Background

The novel coronavirus disease (COVID-19) emerged from China in 2019 and rapidly spread worldwide. Patients with metabolic comorbid conditions are more susceptible to infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Metabolic syndrome is a constellation of interlinked metabolic risk factors that predispose patients to increased risk of complications. Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome and non-alcoholic steatohepatitis (NASH) is the aggressive form of NAFLD.

Objective

The aim of this study is to determine the relationship between metabolic syndrome components and the risk of COVID-19.

Methods

We reviewed data from a large commercial database (Explorys IBM) that aggregates elec

SUBMITTER: Ghoneim S 

PROVIDER: S-EPMC7480663 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature